In the Trump administration's campaign to promote healthy eating, Robert F. Kennedy Jr. has not stopped at his slogan urging people to "eat re…

The Food and Drug Administration is proposing a system for approving customized drugs and medical treatments for patients with rare or hard-to-treat diseases. The pathway laid out Monday is aimed to approving one-of-a-kind therapies, including those using emerging gene-editing technology. It's a shift long sought by patients, advocates and researchers focused on rare diseases, which often do not fit within the pharmaceutical industry's business model. For many rare diseases, drug companies have had little financial incentive to develop new treatments. The FDA proposal, if finalized, would codify a path for drugmakers and researchers to study and commercialize treatments without conducting large, expensive clinical trials.

The Trump administration is set to launch TrumpRx, a website to help patients buy prescription drugs directly from manufacturers at discounted rates. White House press secretary Karoline Leavitt announced Thursday's expected unveiling in a social media post. The website is not a purchasing platform but directs users to drugmakers' own sites. President Trump first mentioned TrumpRx in September, highlighting deals with pharmaceutical companies to lower drug prices. The website's release faced delays, but it now showcases efforts to reduce costs through agreements with major companies like Pfizer and AstraZeneca. However, the actual savings for consumers remain unclear.

Meals and snacks with "GLP-1 Friendly" labels on the packaging are becoming more common as a growing number of Americans try obesity drugs like Wegovy and Zepbound to lose weight. Nestle and Conagra have put the labels on some of their frozen meals. Food chains like Smoothie King and Chipotle are introducing menu items targeting GLP-1 users. Dietitians say the nutritional needs of people taking the medications aren't that different from the general population's. They need to get enough protein to maintain muscle mass as they lose weight. Fiber is important to prevent constipation. Dietitians recommend reading food labels carefully. Some products marketed to GLP-1 users contain high amounts of saturated fat and sodium.

The Trump administration says pharmaceutical companies have agreed to slash the Medicare prices for 15 prescription drugs after months of negotiations and that it's expected to produce billions in savings for older adults. But the net prices unveiled Tuesday aren't what Medicare recipients will pay at their pharmacy counters because those final amounts will depend on each individual's plan and how much they spend annually on prescriptions. Health Secretary Robert F. Kennedy Jr. touted the deals as part of efforts to address affordability concerns. The negotiation program is mandated by law and began under the Biden administration.

Clinics, advocacy groups and individuals who share abortion-related content online say they are seeing informational posts being taken down even if the posts don't clearly violate the platforms' policies. The groups, in Latin America and the U.S., are denouncing what they see as censorship even in places where abortion is legal. Companies like Meta say their policies have not changed, and experts attribute the takedowns to over-enforcement. But abortion advocates say the removals have a chilling effect even if they are later reversed, and navigating platforms' complex systems of appeals is difficult, if not impossible.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many. Coverage also continues to shift or restrict how patients get prescriptions. Doctors say the patchy coverage and costs force them to get creative in treating patients. But there's hope that prices for the injectable drugs may fall more in the future, especially once pill versions enter the market.

IV therapy clinics are springing up around the country, touting quick ways to recover from a hangover or a hard workout. But doctors and regulators preach caution before plunging into a visit. The service has been on a growth spurt since the COVID-19 pandemic, offering drips that also aim to boost energy levels or immune systems or deal with things like joint pain. Regulators worry about who delivers the treatments, the source of any pharmaceuticals used and how the services are provided. Customers should come prepared to ask questions before they get connected.